S&P 500   3,091.84 (+0.16%)
DOW   27,691.49 (+0.00%)
QQQ   201.54 (+0.29%)
AAPL   261.81 (-0.15%)
FB   194.47 (+2.56%)
MSFT   147.07 (+0.66%)
GOOGL   1,297.21 (-0.08%)
AMZN   1,778.00 (+0.36%)
CGC   19.25 (-5.17%)
NVDA   209.61 (+0.69%)
MU   46.90 (+1.38%)
BABA   186.97 (+0.14%)
GE   11.42 (+0.62%)
TSLA   349.93 (+1.40%)
T   39.17 (-0.51%)
AMD   36.71 (+1.10%)
F   9.04 (-0.44%)
ACB   3.57 (-1.38%)
PRI   129.95 (+0.56%)
NFLX   292.01 (-0.74%)
BAC   33.09 (-0.27%)
GILD   64.32 (-0.50%)
DIS   138.58 (+1.35%)
S&P 500   3,091.84 (+0.16%)
DOW   27,691.49 (+0.00%)
QQQ   201.54 (+0.29%)
AAPL   261.81 (-0.15%)
FB   194.47 (+2.56%)
MSFT   147.07 (+0.66%)
GOOGL   1,297.21 (-0.08%)
AMZN   1,778.00 (+0.36%)
CGC   19.25 (-5.17%)
NVDA   209.61 (+0.69%)
MU   46.90 (+1.38%)
BABA   186.97 (+0.14%)
GE   11.42 (+0.62%)
TSLA   349.93 (+1.40%)
T   39.17 (-0.51%)
AMD   36.71 (+1.10%)
F   9.04 (-0.44%)
ACB   3.57 (-1.38%)
PRI   129.95 (+0.56%)
NFLX   292.01 (-0.74%)
BAC   33.09 (-0.27%)
GILD   64.32 (-0.50%)
DIS   138.58 (+1.35%)
Log in

iCo Therapeutics Stock Price, Forecast & Analysis (CVE:ICO)

C$0.09
+0.00 (+5.88 %)
(As of 11/12/2019 04:00 PM ET)
Today's Range
C$0.09
Now: C$0.09
C$0.09
50-Day Range
C$0.08
MA: C$0.10
C$0.13
52-Week Range
C$0.05
Now: C$0.09
C$0.15
Volume47,500 shs
Average Volume422,465 shs
Market CapitalizationC$13.56 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
iCo Therapeutics Inc., a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat sight and life threatening diseases. Its in-licensed product candidates include iCo-008, a human monoclonal antibody, which is in Phase II clinical trial to treat sight threatening ocular allergies and various systemic disease indications; and Oral AmpB Delivery System that is in pre-clinical stage used for the treatment of systemic fungal infections. The company was founded in 2005 and is headquartered in Vancouver, Canada.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-604-6029414

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Cash FlowC$0.00 per share
Book ValueC$0.00 per share

Profitability

Miscellaneous

EmployeesN/A
Market CapC$13.56 million
Next Earnings Date12/5/2019 (Estimated)
OptionableNot Optionable

Receive ICO News and Ratings via Email

Sign-up to receive the latest news and ratings for ICO and its competitors with MarketBeat's FREE daily newsletter.


iCo Therapeutics (CVE:ICO) Frequently Asked Questions

What is iCo Therapeutics' stock symbol?

iCo Therapeutics trades on the Canadian Venture Exchange (CVE) under the ticker symbol "ICO."

When is iCo Therapeutics' next earnings date?

iCo Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, December 5th 2019. View Earnings Estimates for iCo Therapeutics.

Has iCo Therapeutics been receiving favorable news coverage?

Media headlines about ICO stock have been trending very negative this week, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. iCo Therapeutics earned a media sentiment score of -3.2 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the next several days. View News Stories for iCo Therapeutics.

Who are some of iCo Therapeutics' key competitors?

What other stocks do shareholders of iCo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other iCo Therapeutics investors own include iCo Therapeutics (ICOTF), Theratechnologies (TH), Nemaska Lithium (NMX), Aurora Cannabis (ACBFF), Freeport-McMoRan (FCX), Aurora Cannabis (ACB), Regulus Therapeutics (RGLS) and Dextera Surgical (DXTR).

Who are iCo Therapeutics' key executives?

iCo Therapeutics' management team includes the folowing people:
  • Mr. Andrew J. Rae M.B.A., BSc, MBA, Co-Founder, CEO, Pres & Director (Age 52)
  • Mr. Michael Liggett CPA, CA, Bsc. Pharm., CFO, Corp. Sec. & Director (Age 59)
  • Dr. Peter Hnik M.D., MHSc, Chief Medical Officer (Age 63)

How do I buy shares of iCo Therapeutics?

Shares of ICO and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is iCo Therapeutics' stock price today?

One share of ICO stock can currently be purchased for approximately C$0.09.

How big of a company is iCo Therapeutics?

iCo Therapeutics has a market capitalization of C$13.56 million. View Additional Information About iCo Therapeutics.

What is iCo Therapeutics' official website?

The official website for iCo Therapeutics is http://www.icotherapeutics.com/.

How can I contact iCo Therapeutics?

iCo Therapeutics' mailing address is 760-777 Hornby St, VANCOUVER, BC V6Z 1S4, Canada. The company can be reached via phone at +1-604-6029414.


MarketBeat Community Rating for iCo Therapeutics (CVE ICO)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  43 (Vote Outperform)
Underperform Votes:  48 (Vote Underperform)
Total Votes:  91
MarketBeat's community ratings are surveys of what our community members think about iCo Therapeutics and other stocks. Vote "Outperform" if you believe ICO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/12/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel